Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Inclusion Criteria: * 1\. Voluntarily participate in the clinical study; fully understand and be informed about the study and sign the Informed Consent Form (ICF); willing to comply with and capable of completing all trial procedures. * 2\. Diagnosed with DLBCL according to 2022 revised WHO lymphoma classification standards based on pathological diagnosis by the research center. For the dose-expansion phase, BCL-2 positivity (≥50% by IHC) is required. * 3\. Age 18-70 years. * 4\. No prior systemic anti-lymphoma therapy. * 5\. Adequate organ and bone marrow function. * 6\. At least one measurable or evaluable disease site according to the Lugano 2014 lymphoma efficacy evaluation criteria. * 7\. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Exclusion Criteria: * 1\. Lymphoma involvement in the central nervous system or meninges. * 2\. Active infections. * 3\. Uncontrolled clinical cardiac symptoms or diseases. * 4\. Currently using (or unable to stop at least one week prior to the first dose) a known CYP3A strong inducer or strong inhibitor. * 5\. Pregnant and lactating women, and subjects of childbearing age who do not want to use contraception. * 6\. History of Human Immunodeficiency Virus (HIV) infection and/or Acquired Immunodeficiency Syndrome (AIDS). * 7\. Patients with mental disorders or those unable to provide informed consent